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Abstract
Background: In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine
to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether. The change in 1993
raised concerns about whether it had occurred timely and whether it had potentially led to early development of
Plasmodium falciparum resistance to SP. This case study examined evidence from Malawi in order to assess if the policy
changes were justifiable and supported by evidence.
Methods: A systematic review of documents and published evidence between 1984 and 1993, when
chloroquine was the first-line drug, and 1994 and 2007, when SP was the first-line drug, was conducted
herein. The review was accompanied with key informant interviews.
Results: A total of 1287 publications related to malaria drug policy changes in sub-Saharan Africa were identified.
Using the inclusion criteria, four articles from 1984 to 1993 and eight articles from 1994 to 2007 were reviewed.
Between 1984 and 1993, three studies reported on chloroquine poor efficacy prompting policy change according to
WHO’s recommendation. From 1994 to 2007, four studies conducted in the early years of policy change reported a
high SP efficacy of above 80%, retaining it as a first-line drug. Unpublished sentinel site studies between 2005 and 2007
showed a reduced efficacy of SP, influencing policy change to lumefantrine-artemether. The views of key informants
indicate that the switch from chloroquine to SP was justified based on local evidence despite unavailability of WHO’s
policy recommendations, while the switch to lumefantrine-artemether was uncomplicated as the country was
following the recommendations from WHO.
Conclusion: Ample evidence from Malawi influenced and justified the policy changes. Therefore, locally generated
evidence is vital for decision making during policy change.
Keywords: Malaria, Anti-malarial drug policy, Chloroquine, Sulfadoxine-pyrimethamine, Lumefantrine-artemether, Malawi
Background
Research is critical in providing information that can be
used for decision making and policy change [1, 2]. For
instance, WHO emphasized the importance of evidence
when developing policy recommendations on the use of
Intermittent Preventive Treatment of malaria in preg-
nancy with sulfadoxine-pyrimethamine (SP) after review-
ing published evidence from various research findings in
malaria-endemic regions, including Malawi [3]. On the
other hand, experience from many countries has shown
how research conducted within the country informs pol-
icy [1]. As such, research conducted within a country
with valid results is more appropriate to be used to in-
form policy even though evidence from multi-country
studies is more effective for convincing policymakers [1].
However, despite the overwhelming scientific evidence,
policy change is not straight forward since it takes into
consideration many factors, including the political envir-
onment, costs of alternative choices and stakeholders’
views [4, 5]. Choosing the right drug that is efficacious
in the treatment of a disease is one step towards policy
change, but the change process is often long and tedi-
ous, as it involves various stakeholders from both the
public and private sectors [5, 6].
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The treatment of uncomplicated malaria has, over the
years, undergone transitions worldwide, owing to the de-
velopment of resistance of the Plasmodium species to
first-line anti-malarial drugs [7]. In a few countries in sub-
Saharan Africa (SSA), such as Zambia, Kenya and
Tanzania, efficacy data from in vivo studies on chloro-
quine (CQ) resistance led to policy changes in anti-
malarial drug treatment from CQ to SP [1, 8, 9]. However,
in most SSA countries, the process for health policy-
making has proven to be a complex process [6, 10, 11].
For instance, experience from drug policy change in
Kenya, from CQ to SP, revealed difficulties in translating
data and the process was complicated, with limited op-
tions, unknown adverse effects of replacement therapies,
cost, and the limited guidance on factors pertinent to
changing the drug policy for malaria [9]. In addition, many
of the SSA countries are poor and policy change decisions
are highly influenced by their economic budget consider-
ations [12]. This was the case in Sudan, where the decision
to change the policy for anti-malaria drug treatment was
delayed despite the evidence of drug resistance to CQ
[13].
Malawi, as one of the resource-limited countries in
SSA, experienced changes in anti-malarial drug policies
amid concerns over P. falciparum resistance to the first-
line anti-malarial drugs and became the first country to
change the treatment policy from CQ to SP in 1993 [14]
and later to lumefantrine-artemether (LA), an artemisin-
based combination therapy (ACT), in 2007 [15].
However, despite the historical changes in first-line anti-
malarial treatment regimens, in particular from CQ to
SP, many questions were raised as to whether the change
had been done too early and whether the new drugs
would develop resistance quickly [16]. These concerns
were raised as a result of uncertainty surrounding the
usage of clear-cut evidence on drug efficacy from within
the country or region.
A systematic review and documents review were con-
ducted to examine whether evidence from past research
on anti-malarial drug efficacy conducted in Malawi in-
fluenced anti-malarial drug policy changes from CQ to
SP and SP to ACT, amidst economic, political and health
systems challenges. In addition, views from key infor-
mants were sought on their experience and general per-
ceptions on the policy changes. Results from this case
study provide valuable insights into whether the policy
changes were justifiable amidst the challenges and the
unforeseen uncertainties with the anti-malarial drug pol-
icy change in Malawi.
Conceptual framework
A case study approach was adopted in order to under-
stand specific issues that were involved in the anti-malaria
drug policy changes. This approach was appropriate as it
sought to gain an in-depth understanding of the basis for
the policy changes in consideration to the concerns raised.
A case study attempts to gain an insight into a single occa-
sion on how it occurred through the experiences of those
directly involved in the process. Therefore, getting a few
answers from the individuals involved in the case enriches
the study itself [17].
This case study forms part of the process in under-
standing the usage of malaria research with the objective
of developing a framework that can be used to facilitate
the utilization of malaria research evidence for policy de-
velopment in Malawi. The main purpose of developing
this framework was to facilitate adoption of malaria re-
search for policy development, hence maximizing on the
limited resources available in the country. It was there-
fore guided by exploring the institution set up and the
barriers and facilitators on the evidence-to-policy
process in Malawi.
One of the most important aspects for policy change
is the availability of evidence to justify the change. As
previously mentioned, the policy changes that occurred
in Malawi came with many reservations. Therefore, the
basis for the policy decisions needed to be justified. One
of the justifications is the availability of evidence. This
case study explores whether there was sufficient research
evidence to justify Malawi’s policy changes. This study
was conceptualized under the philosophy that suffi-
cient and locally generated evidence is required to
justify policy change.
This paper focuses on the availability of research evi-
dence; hence, it highlights evidence from efficacy studies
on levels of first-line anti-malarial drug regimens and
their alternative drugs, which formed the basis for deci-
sion making in the policy changes. In addition, the views
of key individuals who were directly involved in the pol-
icy changes with regards to the policy changes are
presented.
Methods
The study involved three approaches namely, systematic
review of published evidence, review of key documents
and key informant in-depth interviews.
Systematic review
A comprehensive literature search was conducted in
September 2014. Relevant articles were also searched using
the bibliography of all reviewed articles. Combinations of
the following specific key words relating to malaria drug ef-
ficacy were searched by using the Medical Subject Heading
(MeSH) strategy: chloroquine, Fansidar or sulfadoxine-
pyrimethamine, Fanasil, pyrimethamine drug combination,
lumefantrine-artemether or artemether-lumefantrine com-
bination, and sub-Saharan Africa or Malawi. The search in-
cluded articles from the periods 1984 to 1993, when CQ
Mwendera et al. Health Research Policy and Systems  (2016) 14:41 Page 2 of 14
was the first-line anti-malarial drug for uncomplicated mal-
aria in Malawi, and from 1994 to 2007, when SP was the
first-line drug before being replaced by LA. The following
combinations were used during the search: (“key word”[-
Supplementary Concept]) AND “Malawi”[Mesh] Filters:
From 1984/01/01 to 1993/12/31, (“key word”[Supplemen-
tary Concept]) AND “sub-Saharan Africa”[Mesh] Filters:
From 1984/01/01 to 1993/12/31), “key word”[Mesh] AND
“Malawi”[Mesh] AND (“1994/01/01”[PDAT] : “2007/12/
31”[PDAT]), “key word”[Mesh] AND “sub-Saharan
Africa”[Mesh] AND (“1994/01/01”[PDAT] : “2007/12/
31”[PDAT]). The databases searched were Ovid, MED-
LINE, PubMed, and Google scholar.
Selection criteria
Randomized control trials and cohort studies were in-
cluded on the basis of the following criteria: (1) studies
on treatment efficacy for CQ, SP and LA, and (2) studies
comparing the efficacies of first-line drugs, i.e. CQ or SP
with alternative drugs. Two independent co-authors
judged the eligibility of the studies and disagreements
were resolved by consensus.
Analysis approach
Quality assessment of the papers was conducted using
the Munn et al. [18] newly developed and tested tool for
the critical appraisal of prevalence studies. The purpose
was to check whether the research conducted provided
tangible evidence for policymaking. This involved exam-
ining the methodology used and the findings of the
study in comparison to the recommended WHO guide-
lines to prompt anti-malarial drug policy change.
Document review
Key documents narrating the process of change such as
memos, minutes and reports were sought. In addition,
anti-malarial drug policy documents [19–21] were
reviewed to examine the extent to which they made ref-
erence to the published research and, in this way, estab-
lish the link of the study findings with policy and
guideline development.
Key informant interviews
This involved interviewing individuals, such as policy-
makers and researchers, who were directly involved in
the policy changes in order to capture their views on
how evidence was utilized and their general opinions on
the changes. Hence, a purposive sampling technique was
employed in identifying the key informants. In total, 12
individuals were identified and interviewed. There were
10 senior malaria researchers who were involved in the
production of evidence used during the policy decisions,
of which five were part of the national malaria advisory
committee and two were policymakers, including the
director for the National Malaria Control Programme.
Table 1 highlights the experience, current position and
role played by the key informants during the policy
changes.
All the interviews were conducted by the Principle In-
vestigator, who was able to probe and explore in-depth
issues based on the conceptual framework of the study.
Table 1 Details of key informants (KIs) including their roles in the policy changes
KI Sex Current position Experience Role during policy change
1 Male Child health and development specialist 9 years current position Researcher
2 Male Pharmacologist, College of Medicine (COM) Over 10 years in malaria research Researcher
3 Male Medical epidemiologist – Director of Malaria
Alert Center (MAC), COM
10 years current position Researcher and advisor
4 Male Senior Scientist, Malawi-Liverpool-Wellcome
Trust Clinical Research Programme
More than 40 years in paediatric
malaria research
Researcher and advisor
5 Female Retired Paediatrician and Director of MAC, COM More than 30 years in clinical and
malaria research
Researcher and advisor
6 Male Paediatrician, Ministry of Health More than 30 years in clinical and
malaria research
Researcher and advisor
7 Male Paediatrician, Ministry of Health More than 40 years in clinical and
malaria research
Researcher and advisor
8 Male Clinical Trialist 6 years in current position Researcher
9 Male Entomologist, MAC, College of Medicine Over 10 years current position Researcher
10 Male Medical epidemiologist, College of Medicine More than 15 years in maternal and
child health
Researcher
11 Male Chief of Health Services – Ministry of Health More than 10 years in clinical and
malaria research
Researcher and policymaker
12 Female Director of the National Malaria Control
Programme, Ministry of Health
5 years current position Policymaker
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The interviews were conducted in English using a semi-
structured interview tool, whose development was
guided by the interview schedule for assessing research
utilization in policymaking [11].
Ethics and consent approval
Ethical approval was sought from the Malawi National
Health Sciences Research Committee and the University
of Pretoria Faculty of Health Sciences Research Ethics
Committee during the protocol development. The par-
ticipants were requested to provide consent approval, to
interview and record, before the interviews.
Themes covered in the in-depth interviews
The interviewees were asked about their perceptions on
the policy changes with specific themes covering (1) the
availability of evidence for decision making during the
policy changes, this verified whether there was enough
evidence to form the basis of the decisions that led to
the policy changes, (2) the timing of policy changes, this
explored if the policy changes were justifiable and made
at the right time, and (3) challenges encountered during
the policy changes.
Data management and analysis
The recordings were transcribed and coded based on the
themes, the software Nvivo 9 was used to organize the
data, while verbatim quotes were used to illustrate con-
cepts and support the conclusions, and in order to bring
reality to the situations studied.
Analysis was based on Giorgi’s phenomenological ap-
proach, which focuses on the experiences that partici-
pants have undergone or through shared life experiences
from others that influence their perceptions. This ap-
proach documents the findings from the interviewee’s
point of view in order to collect the descriptions of their
lived world with respect to interpretations in meaning of
the phenomena being described [22].
Results
Systematic review
A total of 1287 relevant publications from SSA were
identified using the developed systematic review criteria.
After applying the inclusion and exclusion criteria, 12
publications from Malawi remained, with four articles
identified from 1984 to 1993 and eight articles from
1994 to 2007 (Fig. 1).
Publications between 1984 and 1993
The review identified four studies that qualified for ana-
lysis (Table 2). Khoromana et al. [23] instituted a study
that explored the efficacy of CQ in children under five at
two doses of 10 mg/kg and 25 mg/kg. The study was
conducted in six sentinel surveillance sites in Malawi
across the three regions where malaria transmission oc-
curs throughout the year. The results from these sites
were similar. The overall parasitological failure on day 7
of follow-up of CQ was 57%, ranging from 41% to 65%.
Despite the poor parasite clearance even at a higher
dose, CQ was retained as the first-line drug for the treat-
ment of uncomplicated malaria because of its lower cost
and availability compared to alternative therapies.
Heymann et al. [24] carried out a study that compared
the efficacy of CQ to amodiaquine (AQ) and SP in chil-
dren under five. Parasitological failure on day 7 of
follow-up for CQ was at 41%, while AQ had a 97% clear-
ance and SP had a 100% clearance. On the 21-day
follow-up period, AQ and SP were further compared in
relation to recrudescence, with 34% of recrudescence oc-
curring in the AQ group while none occurred in the SP
group. Bloland et al. [25] compared the efficacy of CQ
and SP in Kenya and Malawi and results from Malawi
showed that there was 82.3% parasitological failure in
the 28-day follow-up period in the CQ group, while 70%
in the SP group exhibited parasitological response. Blo-
land et al. [25] concluded that CQ was no longer an
effective drug for treating malaria and hence recom-
mended SP as its replacement.
Later, Heymann et al. [26] performed an efficacy study
of CQ on parasitaemia during pregnancy. The study
found that CQ had a 23% protective efficacy; 37% of the
subjects had P. falciparum infection despite taking CQ
during the study period.
Publications between 1994 and 2007
The era of 1994 to 2007 saw the use of SP as the
first-line drug for the treatment of uncomplicated
malaria. The review identified eight studies that quali-
fied for analysis (Table 3). Nwanyanwu et al. [14] ex-
amined the efficacy of SP when it had just been
adopted after anecdotal and written reports about P.
falciparum’s resistance to SP. The study found that
SP was still very efficacious as it showed parasite
clearance in 98.6% of the subjects by day 7 of follow-
up. Similarly, Verhoeff et al. [27] conducted a study
to assess the efficacy of SP just 2 years after its intro-
duction. SP was found to be efficacious as it had a
90.5% parasitological success clearance rate on day 14
of follow-up. These findings built confidence in the
efficacy of SP and removed uncertainties about the
drug among clinicians. Nwanyanwu et al. [28]
assessed the efficacy of SP 5 years after its widespread
use. The study was conducted in seven sites across
the country – three with high transmission and four
with low transmission. The study found that parasito-
logical resistance to SP (RII and RIII) ranged from 7%
to 19%; with one site reaching up to 36%. The level
of treatment failure was at 0.9%. It was thus
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concluded that the efficacy of SP remained at an ac-
ceptable level and should therefore be maintained as
the first-line drug for treatment of uncomplicated
malaria. Takechi et al. [29] assessed the status of anti-
malarial drugs in Malawi through an in vivo study for
SP only and in vitro study for SP, CQ, mefloquine,
quinine and halofantrine. The in vivo results showed
that SP was efficacious by clearing the parasites by
day 14 of follow-up in 83.1% of the patients, while
13.8% of the patients failed to clear the infections by
day 7 (RII/RIII). The in vitro study, however, showed
dissimilar results, as 62.1% of the isolates showed re-
sistance to SP, while resistance was only 3.4% in CQ,
3.2% in mefloquine, 5.7% in quinine and 5.9% in halo-
fantrine. Although SP showed significant parasite
clearance, the rate of failure had increased from less
than 3% found by Nwanyanwu et al. [14] to 13.8% by
Takechi et al. [29], indicating a deteriorating efficacy
of SP.
MacArthur et al. [16] conducted a clinical trial to
compare the efficacy of SP and mefloquine as an alterna-
tive drug after surveillance data had indicated P. falci-
parum’s resistance to SP. The study showed poor
efficacy on day 14 of follow-up in both SP and meflo-
quine, as a combined parasite failure of RII and RIII
were 20% and 22%, respectively. The MacArthur et al.
[16] study was one of the early studies to report on the
deteriorating efficacy of SP. Therefore, the authors rec-
ommended that other alternative drugs should be con-
sidered and tested. Sulo et al. [30] conducted a year-long
study in Kenya and Malawi to measure the annual inci-
dence of malaria in two groups that were treated with ei-
ther SP or chlorproguanal-dapsone (Lapdap) as an
alternative therapy. The 7-day follow-up period results
from Malawi showed that the mean annual malaria inci-
dence was 2.8 compared to 2.2 in the groups treated
with SP and Lapdap, respectively. There was a 5.4%
treatment failure in the Lapdap group compared to
Fig. 1 A flow chart of the selection process of publications for inclusion in the review
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Table 2 Characteristics of malaria publications from Malawi between 1984 and 1993
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Table 3 Characteristics of malaria publications from Malawi between 1994 and 2007
No. Publication Drug(s)
under study
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In vivo efficacy
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Table 3 Characteristics of malaria publications from Malawi between 1994 and 2007 (Continued)
5 MacArthur et al.
[16]; year of study,
1998
SP and MF A randomised trial to
compare the efficacy of SP
and MF, a potential
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Clinical Response
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89.8% in MF group;
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and 1.64 ± 1.67 g/
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first-line antimalarial
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20.1% in the SP group. However, Lapdap was later found
to have major negative side effects and was withdrawn
[31]. In other related studies, Plowe et al. [32] published
their findings from an open-label drug-efficacy test for
SP that was conducted from 1998 to 2002. The authors
established that SP had maintained a good efficacy rate
during the 14-day follow-up period from the time it had
been adopted, with a clinical response rate of 80% or
higher. Msyamboza et al. [33] conducted their study to
assess the efficacy of SP in pregnant women in a rural
clinic with high malaria transmission. They found that
parasitological failure was at 11%. Msyamboza et al.’s
[33] findings showed that resistance patterns in pregnant
women followed those observed in children under five
and the level of SP efficacy was still at an acceptable
level.
Document review
Availability of records posed a major challenge, in par-
ticular minutes and memos were not available for the as-
sessment. Therefore, document review was based on a
report outlining the policy change from CQ to SP [34],
the 2005 Malawi anti-malarial drug efficacy study [35],
and the anti-malaria drug policy guidelines [19–21].
The change from CQ to SP
In 1984, Malawi established its basic structure for the
malaria control program, whose duty was the develop-
ment of the national malaria control policy to guide in-
terventions aimed at addressing the malaria burden in
the country. The policy outlined a 5 year plan including
the guidelines for malaria treatment. It was recognized
that evidence was critical in the development of this pol-
icy. Therefore, several studies were conducted between
1984 and 1989 that provided evidence for the malaria
treatment policy development.
In this regard, an understanding of the dynamics of
malaria as a disease in children was required and hence
the National Malaria Research Project instituted oper-
ational research with the aim of assessing the impact of
malaria in children and to improve treatment strategies.
This study found that the overall infant mortality rate in
Mangochi district was at 163 per 1000 live births, with a
neonatal mortality rate of 49 per 1000 births and a post-
neonatal mortality rate of 111 per 1000 births. However,
no specific cause of death was identified in the neonatal
period, yet in the post-natal period malaria-related
symptoms were identified to be associated with the
deaths. It was also revealed that 70% of the deaths oc-
curred within 7 days of the onset of illness. The study
further found that almost two thirds of the deaths oc-
curred at home with 53% and 70% of deaths in neonates
and post-neonates, respectively.
This study played a major role in defining the impact
of malaria. The findings showed that a high infant mor-
tality rate occurred in rural Malawi and provided an esti-
mate of deaths attributed to malaria with recognition
that most deaths occurred in the community than in
health facilities. These findings were significant in the
formulation of the 1990 National Plan for Malaria Con-
trol in which strategies for implementation were im-
proved by emphasizing the prompt identification and
treatment of malaria in children at community level. For
policy implementation, it ensured the availability of
drugs at all levels of healthcare, training of community
volunteers and health workers in effective case manage-
ment, and the need for rolling out health education in
the communities to inform caregivers on recognizing
malaria-related symptoms and seeking effective malaria
treatment.
Concerns were also raised about the emerging of CQ
resistance and the need of assessment of the malaria pol-
icy, which led to the recognition of a systematic ap-
proach in evaluating the malaria control policies. One of
the strategies was the identification of six sentinel sites
in Malawi for surveillance of malaria focusing on para-
sitological and clinical response of anti-malarial drugs.
This involved in vivo studies testing the efficacy of CQ
in single doses of 10 mg/kg and 25 mg/kg body
weight [23].
In vivo drug efficacy studies for alternative drugs to re-
place CQ were also conducted involving two doses of
AQ at 10 mg/kg and 25 mg/kg, and SP at 25 mg/
kg [24].
For purposes of understanding the clinical response, a
study was undertaken to compare the clinical response
of children to CQ and SP. The study looked at three
clinical indicators that included the presence of at least
75% of children with P. falciparum infection and corre-
lated with parasite density, history of fever during the
preceding 48 hours, and history of altered activity level
during the preceding 48 hours, and axillary temperature
of greater that 37.2 °C. The findings showed that, on the
second day, CQ had a rapid effect in addressing symp-
toms consistent with rapid schizonticidal activity and
antipyretic effect. However, on the seventh and four-
teenth days the clinical failure rates for CQ were not sig-
nificantly higher than for SP.
The findings from these studies were utilized in devel-
oping the malaria therapy policy in 1985, which resulted
in discontinuing the routine treatment of children under
five and the country adopted the presumptive treatment
of fever with CQ at a dose of 25 mg/kg. The studies also
influenced the retention of CQ as the first-line drug in
treating uncomplicated malaria despite parasite resist-
ance, since it demonstrated a positive clinical response
by the seventh day of treatment, and its wide availability
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and general safety in its use. It was recommended from
the findings that AQ and SP become therapies of choice
after CQ treatment failure in children under five.
The increased concerns of CQ resistance led to imple-
mentation of a re-evaluation of in vivo studies to assess
the efficacy of CQ, SP and AQ at the dosages of 25 mg/
kg. The findings showed the deterioration of CQ efficacy
while AQ showed poorer response on day 7 compared
to SP indicating parasite resistance. These studies were,
however, not considered sufficient to warrant policy
change although a routine drug assessment policy was
put in place.
The national malaria control committee evaluated its
initial 5 year plan from 1984 to 1989 to feed into its next
strategic plan from 1989 to 1993. One of the major find-
ings from this evaluation was the maintained rapid in-
crease of malaria-related morbidity and mortality as the
hospitalizations of children under five increased by 43%
and malaria case fatality rose by 30%. Therefore, the op-
eration research agenda focused on supporting studies
that could provide evidence in refining the malaria con-
trol policy. The main area of focus was the assessment
of alternative drugs that could replace CQ for treatment
of uncomplicated malaria. In addition to this, the studies
assessed the clinical, haematological and parasitological
drug response. Based on these studies conducted in
Malawi, WHO adopted the qualification of an anti-
malarial drug as efficacious for use in treating uncompli-
cated malaria in children under five if it was able to
adequately alleviate the symptoms of the disease, clear
the parasites and allow a tolerable parasite-free interval
for haematological recovery [25].
Bloland et al. [25] conducted and published the
Karonga and Mangochi follow-up studies that com-
pared the parasitological and clinical responses of CQ
and SP. The publication has also been reviewed in
the systematic review. As a direct result of these
studies, the treatment guidelines of the first-line drug
for uncomplicated malaria changed from CQ to SP in
1992. The policy change was fully implemented in
1993, when adequate stocks of SP were procured. SP
was also advantageous since it was easy to administer
as it was tasteless and required a single dose leading
to increased compliance.
Sentinel surveillance report for the change of SP to LA
In January 2005, the National Malaria Control Programme
convened a meeting with its supporting committees – the
Malaria Advisory Committee and the National Malaria
Technical Committee. They discussed, among other
things, the need to change the country’s first-line anti-
malaria drug policy after considering that efficacy studies
had shown SP 14-day clinical treatment failure of above
15% that recommended by WHO as the cut-off point,
prompting policy change. Although WHO had recom-
mended ACTs [36] to be the best option for first-line
anti-malarial drugs, there was a need to generate local
evidence in order to make an informed choice on the
optional ACTs available. Therefore, open label ran-
domized efficacy trials targeting children under five in
three sentinel sites during the malaria season com-
menced in April 2005. The objective of the study was
to assess four drug combinations (AQ plus artesunate
(AQ-Art), AQ plus SP (AQ-SP), chlorproguanil-
dapsone plus artesunate (CD-Art), and LA). In
addition, the efficacy of SP was also conducted for
comparison purposes to the new drugs.
The results showed poor efficacy of SP, as it had only
32% of adequate clinical and parasitological response on
day 28, while the other drugs showed over 90%, specific-
ally 100% in AQ-Art, 95% in AQ-SP, 94% CD-Art, and
93% in LA. Thus, all the combination drugs were similar
in superiority to SP. These findings provided the local
evidence for the Malawi government to choose the most
appropriate combination drug for treating uncompli-
cated malaria. Finally, LA was the suitable choice in re-
placing SP.
Policy and guideline documents
The anti-malarial treatment policies and guidelines were
reviewed to assess how they made reference to research
evidence that informed their development. A major chal-
lenge with these documents is that they did not have a
formal reference section that could be assessed as to
what specific study was used in their development. How-
ever, the documents clearly mention the in vivo studies
conducted in the sentinel sites as the major sources of
local evidence that influenced policy changes. The in
vivo studies in the sentinel sites that led to the change of
CQ to SP were published and included in the systematic
review [25], while the unpublished 2005 in vivo efficacy
studies provided the evidence for policy change of SP to
LA [35].
Findings from the key informant interviews
Key informants provided their experiences and views
towards the policy changes and how evidence was
critical in driving the changes. As previously indi-
cated, the main concern for the historical change
from CQ to SP was the uncertainty on the sustain-
ability of SP’s high efficacy on P. falciparum. Hence,
the question was whether the change was justifiable
at that time. Therefore, views of key informants were
sought regarding the change.
Availability of evidence for justification of policy changes
Clinicians and other medical personnel in health facil-
ities observed that CQ was no longer effective in the
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treatment of malaria. As narrated by one of the re-
searchers, who was also a clinician:
“In the mid-1980s, around 1985, clinicians across the
country started observing that people treated with
chloroquine were coming back complaining that they
do not feel better”.
Timing of policy changes
The several reports from the clinicians raised concerns
about using CQ in treating malaria, which prompted the
government of Malawi through the Ministry of Health
to conduct efficacy studies that would provide empirical
evidence to substantiate these reports. The results of
these studies revealed that indeed CQ was not working
and there was need for change [25]. This was acknowl-
edged by one researcher, who is also a paediatrician:
“It was timely, the evidence was clear that chloroquine
wasn’t working at the time, I’m a child specialist so I
actually see the effects or the complications, if the drug
is not working, the children do not get well, some even
die against severe forms of malaria, so seeing that we
decided to make a change, it was quite obvious we
needed the change”.
Another researcher also recounted the need for local
evidence to base the policy decision on:
“And then of course there a was also need for the
research to be done to back up the actual change and
again for Malawi that change came about because of
drug efficacy studies that were carried out over the
years which then meant that it was easy for the policy
makers to certainly say hey its indeed high time to
change because this drug is obviously not working”.
Challenges during policy changes
The main challenge for this change however, was that
there were no clear WHO guidelines for policy changes,
i.e. on what recommended drugs to replace CQ, hence
there was limited support from WHO, as stipulated by
one researcher:
“The first challenge was the fact that there was no
buy-in from WHO.... so WHO was saying who is going
to pay if we are not supporting it…who is going to pay
for this?”
This situation led to Malawi making a strong case of
changing the policy since WHO was concerned with
early development of parasite resistance to SP. However,
based on the data generated locally, increased morbidity
and mortality were a major concern for Malawi. Hence,
further studies were initiated to gather strong evidence.
This was confirmed by one researcher who, on what led
to them conducting efficacy studies, said:
“That then prompted government to consult Center for
Disease Control to help out with investigations on
what was happening, why are several patients treated
coming back complaining of the same signs and
symptoms?”
Therefore, evidence was generated and presented to
the policy decision makers for their next step. It further
showed that the policy change from CQ to SP needed to
be based on tangible, structured evidence. Hence, for
this purpose, the studies provided the evidence required.
From this case study it can be observed that records
were well documented and published regarding the
change from CQ to SP and those studies were published
during this time, including in the early years of change
to SP compared to the change of SP to LA. As
highlighted from one researcher:
“Well at this stage from SP to LA they were following
the WHO recommendations so I suppose people didn’t
worry too much about it, you know, getting track with
what actually was happening but with the earlier
period when we had to change from chloroquine to SP
this was new but the advantage we had was that we
had locally generated data that could not be refuted”.
The WHO plays a vital role in driving policy issues in
the world. It will provide guidelines that countries adapt.
Recommendations from WHO will easily influence deci-
sions for policymakers as they deem that these recom-
mendations are tangible. WHO recommended that the
first-line anti-malarial drugs be replaced by ACT [36];
therefore, in 2005, Malawi had to carry out efficacy stud-
ies that included the assessment of SP in comparison to
ACTs for possible replacement. Hence, the guidelines
were very critical in changing the drug policy from SP to
LA as countries, including Malawi, were following these
recommendations, but the change from CQ to SP had to
rely on strong locally generated evidence to convince
policymakers to make the switch since such guidelines
did not exist at that time.
Discussion
Research has been proven to provide vital evidence for
decision making and, more critically, for policy develop-
ment [2]. Research is critical in resource-limited coun-
tries such as Malawi in order to maximize the usage of
resources. Owing to the constant mutation of the mal-
aria parasite (Plasmodium sp.), there has been a major
challenge in malaria prevention and control [37],
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prompting changes in anti-malarial drug regimens across
the years in Malawi and other malaria-endemic coun-
tries [38]. This case study explored the availability and
usage of research evidence that formed the basis for de-
cision making in the policy changes. This was done
through a systematic review examining published re-
search evidence on malaria drug efficacy studies con-
ducted between 1984 and 1993, and 1994 and 2007,
examination of documents in the form of reports and
policy guidelines to assess their reference to evidence,
and in-depth interviews with key informants directly in-
volved in the generation of evidence during the policy
changes with the objective of soliciting their general
views and perceptions towards the policy changes.
It was found out that there was enough scientific evi-
dence from research conducted from 1984 to 1993 on
CQ resistance to support a change in anti-malarial drug
policy from CQ to SP in Malawi. Secondly, although the
evidence did not come from peer reviewed journals,
studies from sentinel sites conducted between 2005 and
2007 showed a reduced efficacy of SP within Malawi, in-
fluencing a change in first-line anti-malarial treatment
from SP to LA. Views of key informants indicate that
the policy changes were timely enough, although the
change from CQ to SP could have occurred earlier.
These results, therefore, support the proposition that
evidence from drug efficacy studies within Malawi influ-
enced the changes in policy on anti-malarial drug
treatment.
Malawi was the first country in SSA to change its first-
line anti-malarial drug from CQ to SP [14] and, in 2007,
it changed its policy again from SP to LA [21]. Amid the
economic, political and other challenges within the
country, concerns were raised during the policy change
from CQ to SP as to whether the change had occurred
too early and the change’s implications for the quick de-
velopment of resistance to SP [16]. Studies conducted
between 1984 and 1993 provided ample evidence about
the poor efficacy of CQ and the superiority of SP as its
replacement. The objectives of some of the reviewed
studies strongly indicate that the studies were conducted
for purposes of policy formulation [23–25, 39]. The
study by Khoromana et al. [23] was instituted with the
sole purpose of guiding malaria treatment drug policy in
Malawi. However, despite its findings of low efficacy of
CQ in Malawian children, the dosage of 25 mg/kg was
adopted in the treatment of uncomplicated malaria as
the first-line drug. Similar studies with such objectives
to drive policy have also been conducted and published
in other countries [40–42]. A case study on Malawi by
WHO about the development of anti-malarial drug pol-
icy in the period of 1984 and 1993 highlighted the find-
ings by Khoromanana et al. [23] and Bloland et al. [25]
as having provided the important information critical for
policy and guideline changes [43], and these findings
were also acknowledged by Nwanyanwu et al. [14] to
have been used for policy development. These studies
were conducted in different geographical regions and in
areas of high and low transmission during both rainy
and dry seasons. The treatment failure observed from
these studies exceeded the 25% recommended by WHO
as the cut-off point [43], in this way prompting anti-
malarial drug policy change. The studies also presented
the findings of alternative drugs studied [24, 25] and
have shown evidence that SP was more practical as a re-
placement for CQ in this period.
Following the change of the anti-malarial first-line
drug in 1993 to SP, unconfirmed reports of its poor effi-
cacy subsequently led to five efficacy evaluation studies
being undertaken [14, 27–29, 32]. The findings from
these studies showed a maintained high acceptable level
of efficacy of SP and influenced the policy decision to re-
tain it as the first-line anti-malarial drug for treatment of
uncomplicated malaria in Malawi. However, from the
publications assessed between 1994 and 2007, the effi-
cacy of SP was still at a level for it not to warrant policy
change. Since no publications were found after Plowe et
al.’s [32] study, conducted between 1998 and 2002, it
would be difficult to ascertain when SP started losing its
efficacy to levels prompting its removal as a first-line
drug for malaria treatment. However, in 2005, the
Malawi government, through the National Malaria Con-
trol Programme, carried out unpublished efficacy studies
in the sentinel sites in children under five. The
programme tested the efficacies of four combination
drug candidates: AQ-SP, AQ-Art, CD-Art and LA, while
SP was also assessed to provide up-to-date data on its
efficacy for comparison with the new drug candidates.
SP showed deterioration, as it had only 32% of adequate
clinical and parasitological response on day 28, while the
other drugs showed over 90% of adequate clinical and
parasitological response.
Policy development is intricate and not entirely deter-
mined by research evidence [44]. In order to establish
the impact of research on policy and practice, reports
[34] and the Malawi Ministry of Health anti-malarial
drug policy documents [19–21] were reviewed to check
for any references made to research. These documents
did not have a formal reference section. However, the
guidelines clearly referred to regular in vivo studies, as
recommended by WHO [37] and conducted in sentinel
sites in varied geographical regions of the country, to
have been a major factor influencing policy develop-
ment, especially the change from SP to LA.
Generally, WHO develops and updates protocols that
guide anti-malarial drug efficacy studies [45]. This
standardization is necessary in order for those involved
in research to produce comparable and viable results to
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help guide policymaking. However, even when not lim-
ited to these protocols, utilization of randomized control
trials with blinding is essential in order to reduce bias as
much as possible [45]. In this study, only two studies ex-
plicitly indicated to have used randomization [16, 30],
while three studies [16, 23, 30] explained how they ar-
rived at particular sample size using statistical methods.
Nevertheless, evidence from the various malaria studies
from Malawi showed some agreement in outcome of
their findings despite differences in their methodology.
Experiences and views from key informants indicate
that Malawi required ample evidence to change its pol-
icy from CQ to SP when there were no WHO guidelines
to recommend the change. WHO concerns were based
on the fact that changing to SP would lead to parasite
resistance to SP much earlier, which would also be a
concern to neighbouring countries due to border cross-
ing that occur and hence lead to a regional problem.
However, Malawi demonstrated that the change was
eminent and continual monitoring of SP showed that no
parasite resistance developed to levels of concern for
policy change until in 2007, when SP eventually was re-
placed by LA based on WHO recommendations.
As for later changes to ACTs, WHO updated its guide-
lines for countries to follow when switching their first-line
anti-malarial to ACTs [36]. In this regard, many countries
made the changes earlier than Malawi, such as Zambia,
which became the first African country to change from
CQ to LA in 2002 [46]. Kenya switched from SP to LA in
2004 [47] and, by June 2006, 39 African countries had
switched to the WHO recommended ACTs [46]. Malawi
only made its switch in 2007 as it required gathering thor-
ough local evidence from the sentinel sites. As already
highlighted, the change from SP to LA was smooth since
it was done following WHO recommendations.
Conclusions
Substantial malaria drug efficacy studies were conducted
in Malawi, which provided tangible evidence for policy
decision making. The change from CQ to SP was sys-
tematic; at a time when there were no clear WHO
guidelines for changing a drug that loses it efficacy, the
team from Malawi observed that CQ was no longer effi-
cacious and hence carried out studies that provided
strong evidence to justify the change, while unpublished
sentinel surveillance studies provided evidence for policy
change from SP to LA [21]. Consequently, there was jus-
tifiable evidence from efficacy studies conducted within
Malawi that were used for timely policy changes.
Based on the findings, strong locally generated evi-
dence is crucial for policy decision making. In addition,
the study recommends proper record keeping and that
policy documents and guidelines should be formally ref-
erenced to allow tracking of evidence used for their
development. An example of such referenced malaria
guidelines exists in the case of Kenya [48]. In addition,
sentinel surveillance findings should be published so that
they undergo peer review and become readily available
to a wider community. Research and monitoring of drug
efficacy should continue to be conducted according to
the recommendations of the WHO protocols and meth-
odologies in order to ensure quality of the research
results.
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